Lidanserin

Lidanserin
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • 4-(3-{3-[4-(4-fluorobenzoyl)-1-piperidinyl]propoxy}-4-methoxyphenyl)-2-pyrrolidinone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC26H31FN2O4
Molar mass454.542 g·mol−1
3D model (JSmol)
SMILES
  • Fc1ccc(cc1)C(=O)C4CCN(CCCOc2cc(ccc2OC)C3CC(=O)NC3)CC4
InChI
  • InChI=1S/C26H31FN2O4/c1-32-23-8-5-20(21-16-25(30)28-17-21)15-24(23)33-14-2-11-29-12-9-19(10-13-29)26(31)18-3-6-22(27)7-4-18/h3-8,15,19,21H,2,9-14,16-17H2,1H3,(H,28,30)
  • Key:JDYWZVJXSMADHP-UHFFFAOYSA-N

Lidanserin (INN; ZK-33,839) is a drug which acts as a combined 5-HT2A and α1-adrenergic receptor antagonist.[1] It was developed as an antihypertensive agent but was never marketed.[1]

See also

References

  1. 1 2 Allen RC (1989). Annual Reports in Medicinal Chemistry. Academic Press. p. 56. ISBN 978-0-12-040524-4. Retrieved 6 May 2012.
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.